Evidence map›Paper›PMID 39626263›Full record

ReviewThe Journal of experimental medicine2025

Bridging the gap between tumor and disease: Innovating cancer and glioma models.

Stefano M Cirigliano, Howard A Fine

Abstract readReview
In one paragraph

Review in The Journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Impact of Low-Dose X-Ray Radiation Exposure on Lung Cancer Progression.International journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Stefano M CiriglianoDepartment of Neurology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-2397-6263
Howard A FineDepartment of Neurology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-6169-5702

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent advances in cancer biology and therapeutics have underscored the importance of preclinical models in understanding and treating cancer. Nevertheless, current models often fail to capture the complexity and patient-specific nature of human tumors, particularly gliomas. This review examines the strengths and weaknesses of such models, highlighting the need for a new generation of models. Emphasizing the critical role of the tumor microenvironment, tumor, and patient heterogeneity, we propose integrating our advanced understanding of glioma biology with innovative bioengineering and AI technologies to create more clinically relevant, patient-specific models. These innovations are essential for improving therapeutic development and patient outcomes.

Indexed as

GliomaTumor MicroenvironmentAnimalsBrain NeoplasmsDisease Models, AnimalHumansModels, Biological

Identifiers

PMID39626263
PMCPMC11614461

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.